EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025.04.02

Essex Bio-Technology Reports Stellar 2024 Annual Results：Net Profit soars 11.6% to HK$ 307.2 Million, Dividend increases 33.3% Focuses on Strengthening R&D Capabilities and Expanding Market Access

2025.03.26

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Date

Title

2018-10-29

Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018

2018-08-22

Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China

2018-08-10

Group Turnover and Profit in the First Half of 2018 Increased 28.3%

2018-07-24

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-18

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

2018-04-12

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

2018-04-10

Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA

2018-03-16

Group Profit Recorded Growth of 22.8% in 2017

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT